Literature DB >> 15973123

cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP.

Catalina Abad1, Yasmina Juarranz, Carmen Martinez, Alicia Arranz, Florencia Rosignoli, María García-Gómez, Javier Leceta, Rosa P Gomariz.   

Abstract

Crohn's disease (CD) is a chronic inflammatory pathology of the intestine, characterized by diarrhea and weight loss. A healing effect of vasoactive intestinal peptide (VIP) in the murine model of CD based on 2,4,6-trinitrobencene sulfonic acid (TNBS) administration has been previously shown. The aim of this work was to analyze the expression of several mediators related to the inflammatory cascade in colitic and VIP-treated animals. With this aim, mice received either only TNBS or TNBS and VIP treatment on alternate days. cDNA microarray analysis and real-time polymerase chain reaction were performed on total mRNA from colon to study the expression of a battery of proinflammatory molecules such as the enzyme COX-2, the chemokines CX3CL1, CXCL12, CXCL13, CXCL14, CCR5, and CXCR2, and the cytokines interleukin (IL)-1beta, IL-12, IL-18, IL-10, interferon-gamma, and IL-4. TNBS administration induced the expression of all the proinflammatory mediators studied, whereas VIP treatment reduced their levels, increasing the anti-inflammatory IL-10 and the TH2 cytokine IL-4, explaining its beneficial action through inhibition of the inflammatory/TH1 response. These data describe not only the relation of several proinflammatory mediators to the development of TNBS colitis, reporting their time-course, but also show the beneficial action of VIP in this model through complete blockage of the inflammatory cascade and recovery of the colon homeostasis, providing a potential new alternative for CD therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15973123     DOI: 10.1097/01.mib.0000171872.70738.58

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  24 in total

Review 1.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

2.  Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells.

Authors:  Sheri Tinnell Dorsam; Emilie Vomhof-Dekrey; Rebecca J Hermann; Jodie S Haring; Travis Van der Steen; Erich Wilkerson; Goran Boskovic; James Denvir; Yulia Dementieva; Donald Primerano; Glenn Paul Dorsam
Journal:  Mol Immunol       Date:  2010-02-01       Impact factor: 4.407

3.  Vasoactive intestinal peptide enhances TNF-α-induced IL-6 and IL-8 synthesis in human proximal renal tubular epithelial cells by NF-κB-dependent mechanism.

Authors:  Ling Huang; Yiting Tang; Jiao Qin; Yu Peng; Qiongjing Yuan; Fangfang Zhang; Lijian Tao
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

4.  Alleviated mucosal and neuronal damage in a rat model of Crohn's disease.

Authors:  Petra Talapka; Lajos István Nagy; Alexandra Pál; Marietta Zita Poles; Anikó Berkó; Mária Bagyánszki; László Géza Puskás; Éva Fekete; Nikolett Bódi
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

5.  Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells.

Authors:  Rebeca Jimeno; Javier Leceta; Carmen Martínez; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Marina Garín; Mario Mellado; Rosa P Gomariz; Yasmina Juarranz
Journal:  J Mol Neurosci       Date:  2014-05-08       Impact factor: 3.444

6.  Soluble CD83 ameliorates experimental colitis in mice.

Authors:  J Eckhardt; S Kreiser; M Döbbeler; C Nicolette; M A DeBenedette; I Y Tcherepanova; C Ostalecki; A J Pommer; C Becker; C Günther; E Zinser; T W Mak; A Steinkasserer; M Lechmann
Journal:  Mucosal Immunol       Date:  2014-01-15       Impact factor: 7.313

Review 7.  Emerging Roles for Noncanonical NF-κB Signaling in the Modulation of Inflammatory Bowel Disease Pathobiology.

Authors:  Dylan K McDaniel; Kristin Eden; Veronica M Ringel; Irving C Allen
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

8.  Vasoactive Intestinal Peptide Nanomedicine for the Management of Inflammatory Bowel Disease.

Authors:  Dulari Jayawardena; Arivarasu N Anbazhagan; Grace Guzman; Pradeep K Dudeja; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2017-10-19       Impact factor: 4.939

9.  VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.

Authors:  Yossan-Var Tan; Catalina Abad; Yuqi Wang; Robert Lopez; James Waschek
Journal:  Brain Behav Immun       Date:  2014-10-13       Impact factor: 7.217

10.  Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis.

Authors:  Catalina Abad; Gardenia Cheung-Lau; Anne-Claire Coûté-Monvoisin; James A Waschek
Journal:  Neuroimmunomodulation       Date:  2014-10-03       Impact factor: 2.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.